NCT05655221: A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects |
|
|
| Recruiting | 1 | 56 | US | B1344, pegylated conjugate of recombinant human mutated fibroblast growth factor 21, Placebo | Tasly Biopharmaceuticals Co., Ltd. | Nonalcoholic Steatohepatitis | 07/23 | 01/24 | | |
